locallyl effect of Cyclosporin and Dexamethasone in oral lichen planus

Dexamethasone and Cyclosporine , seprarately and in combination in oral lichen planus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013100114713N1

Enrollment

Registered

2013-10-26

Start date

2012-10-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral lichenplanuse. lichen planus

Interventions

Intervention 1: Group 1: Dexamethasone 0.1%,Tid,5ml,6weeks. Intervention 2: Group2: Cyclosporine 0.1%,Tid,5ml,6weeks. Intervention 3: Group3: Dexamethasone 0.05 % + Cyclosporine 0.05 % ,Tid,5ml,6weeks

Treatment - Drugs

Group 1: Dexamethasone 0.1%,Tid,5ml,6weeks

Group2: Cyclosporine 0.1%,Tid,5ml,6weeks

Group3: Dexamethasone 0.05 % + Cyclosporine 0.05 % ,Tid,5ml,6weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria Patients with oral lichen planus diagnosed according to modified WHO criteria ; Painful lesions (VAS = 3-7 ) Exclusion criteria Patients with systemic disease :hypertension, pulmonary disease ,kidney transparent , heart disease , chronic liver disease, poor controlled diabetes ; pregnancy or breast feeding and patients who take sterogene based drugs ; Patients who were under local or systemic agents for lichen planus in last two months ; Patients with history of cancer and use immunomodulating drugs in last two months ; oral lichen planuse concurrence with skin lesion or other mucosal lesion ; Patients who take beta blockers ,diuretics, anticonvulsants, barbiturates and ACE inhibitors ; Patient with complete denture.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lesion size. Timepoint: befor intervation, weekly for 6 weeks. Method of measurement: Thongprasom scoring system.;Pain. Timepoint: befor intervation, weekly for 6 weeks. Method of measurement: visual pain score.	—

Secondary

Measure	Time frame
Candidiasis superimposition. Timepoint: weekly for 6 weeks. Method of measurement: culture.;Telangiectasia. Timepoint: weekly for 6 weeks. Method of measurement: clinical examination.;Atrophy. Timepoint: weekly for 6 weeks. Method of measurement: clinical examination.;Mucosal change. Timepoint: weekly for 6 weeks. Method of measurement: clinical examination.;Taste change. Timepoint: weekly for 6 weeks. Method of measurement: questionnaire form.;Burning sensation. Timepoint: weekly for 6 weeks. Method of measurement: questionnaire form.	—

Measure

Time frame

Candidiasis superimposition. Timepoint: weekly for 6 weeks. Method of measurement: culture.;Telangiectasia. Timepoint: weekly for 6 weeks. Method of measurement: clinical examination.;Atrophy. Timepoint: weekly for 6 weeks. Method of measurement: clinical examination.;Mucosal change. Timepoint: weekly for 6 weeks. Method of measurement: clinical examination.;Taste change. Timepoint: weekly for 6 weeks. Method of measurement: questionnaire form.;Burning sensation. Timepoint: weekly for 6 weeks. Method of measurement: questionnaire form.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactfateme yarmand

Babol University of Medical Science

fateme.yarmand@gmail.com+98 11 1229 1408

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026